BioCentury | Dec 20, 2018
Finance

Third Rock keeps its options open

...Celgene obtained in 2014. The companies also share worldwide rights to Phase I candidate AG-881...
BioCentury | May 25, 2018
Clinical News

Agios reports Phase I safety data for IDH1/IDH2 inhibitor

...Inc. (NASDAQ:AGIO) reported safety data from 93 evaluable patients in a Phase I trial evaluating AG-881...
...abstract ahead of the American Society of Clinical Oncology (ASCO) meeting in Chicago. Agios said AG-881...
...dose-escalation, U.S. trial evaluated once- and twice-daily doses of oral AG-881 in continuous 28-day cycles. AG-881...
BioCentury | Jan 27, 2018
Strategy

Jump-starting growth

...NASDAQ:JNCE), navicixizumab and OMP-313M32 from OncoMed Pharmaceuticals Inc. (NASDAQ:OMED), FT-1101 from Forma Therapeutics Inc. and AG-881...
BioCentury | May 18, 2016
Top Story

Celgene, Agios form new oncology deal, revise another

...in Phase III testing for refractory or relapsed AML. The companies share worldwide rights to AG-881...
BioCentury | Nov 19, 2015
Distillery Therapeutics

Therapeutics: Isocitrate dehydrogenase 1 (IDH1)

...Phase I testing for AML, hematological malignancies and solid tumors. Agios and Celgene also have AG-881...
BioCentury | Jul 20, 2015
Clinical News

AG-881: Phase I started

...evaluate once-daily oral AG-881 in about 150 patients. The companies partnered to develop and commercialize AG-881...
...BioCentury, May 4). Agios Pharmaceuticals Inc. (NASDAQ:AGIO), Cambridge, Mass. Celgene Corp. (NASDAQ:CELG), Summit, N.J. Product: AG-881...
BioCentury | May 4, 2015
Company News

Agios, Celgene deal

...The companies partnered to develop and commercialize AG-881 worldwide. Agios said it expects a Phase I...
BioCentury | May 4, 2015
Analyst Picks & Changes

Analyst picks & changes

...to $103 from $163 after Agios announced plans last week to begin clinical testing of AG-881...
...believes suggests higher risk regarding the company's more advanced AG-120. He suspects Agios is moving AG-881...
...report data from the AG-120 trial in 2H15, which is later than Newman had expected. AG-881...
BioCentury | Apr 30, 2015
Company News

Celgene strikes cancer deals with Agios, Northern Biologics

...licensed its third asset from Agios Pharmaceuticals Inc. (NASDAQ:AGIO), acquiring rights to develop and commercialize AG-881...
...isocitrate dehydrogenase 2 ( IDH2 ). Agios said it expects a Phase I study of AG-881...
Items per page:
1 - 9 of 9